Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
Blood Advances|June 17, 2026
Low-Dose Vemurafenib Plus Rituximab in Front-Line and Relapsed or Refractory Hairy Cell Leukemia: The Scripps RegimenDavid J Hermel, Alan SavenLeukemia & Lymphoma|September 1, 2025
Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemiaDanielle Brazel, David J Hermel, Alan SavenAnnals of Hematology|February 26, 2022
Long-term outcomes of elderly hairy cell leukemia patients treated with cladribineDavid J Hermel, Brian Cheng, Munveer S Bhangoo, et al.Future Science OA|July 22, 2021
ABO phenotype and clinical correlates of COVID-19 severity in hospitalized patientsDavid J Hermel, Samantha R Spierling Bagsic, Carrie L Costantini, et al.Future Oncology (London, England)|February 2, 2022
An observational study of hospitalized COVID-19 patients with cancer in San Diego countyDavid J Hermel, Jason Cham, Samantha R Spierling Bagsic, et al.Expert Review of Anticancer Therapy|October 16, 2004
Cladribine: from the bench to the bedside--focus on hairy cell leukemiaNatalya Greyz, Alan SavenHematology/Oncology Clinics of North America|September 23, 2006
Cladribine in hairy cell leukemiaRajesh Belani, Alan SavenExpert Review of Hematology|August 6, 2019
Novel therapeutics in hairy cell leukemiaAditya Sarvaria, Alan SavenExpert Review of Anticancer Therapy|April 12, 2008
Cladribine in indolent non-Hodgkin's lymphomaDarren S Sigal, Alan SavenMayo Clinic Proceedings|January 4, 2012
My treatment approach to hairy cell leukemiaRahul R Naik, Alan SavenPageof 7